# A Pharmacokinetics Study of AF-130 in Healthy Subjects

> **NCT02652936** · PHASE1 · COMPLETED · sponsor: **Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 80 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** AF-130
- **DRUG:** Placebo comparator

## Key facts

- **NCT ID:** NCT02652936
- **Lead sponsor:** Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02652936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02652936, "A Pharmacokinetics Study of AF-130 in Healthy Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02652936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*